AANS Neurosurgeon | Volume 26, Number 4, 2017


UAB Researchers Discover why Brain Neurons in Parkinson's Disease Stop Benefiting from Levodopa

The mechanism may be therapeutic target to prevent or reverse dyskinesia

Though the drug levodopa (L-DOPA) can dramatically improve Parkinson’s disease symptoms, within five years one-half of the patients using L-DOPA develop an irreversible condition – involuntary repetitive, rapid and jerky movements. This abnormal motor behavior appears only while taking L-DOPA, a it stops if the drug is stopped. However, if L-DOPA is taken again, even many months later, it quickly re-emerges. In research to prevent this side effect and extend the usefulness of L-DOPA – which is the most effective drug treatment for Parkinson’s disease – University of Alabama at Birmingham researchers have uncovered an essential mechanism of this long-term memory for L-DOPA-induced-dyskinesia, or LID. To read more, click here.


Spine World Summit
Jan. 26, 2018 - Jan. 27, 2018; Hong Kong

6th Ottawa Neurosurgery Review Course
Feb. 3, 2018 - Feb. 10, 2018; Ottawa, ON Canada

Winter Clinics for Cranial and Spinal Surgery
Feb. 25, 2018 - Mar. 1, 2018; Snowmass Village, Colo.

Comments are closed.